SAGA Diagnostics

SAGA Diagnostics is a personalized cancer medicine company specializing in molecular genetic analyses of circulating tumor DNA (ctDNA) and tissue biopsies. We leverage cutting-edge liquid biopsy technology to improve the accuracy of cancer diagnosis, treatment monitoring, and ultimately, patient survival. Our ultrasensitive tests detect actionable mutations, enabling personalized treatment strategies and improved patient outcomes. We're making a significant impact on the oncology landscape by providing unparalleled sensitivity and specificity in minimal residual disease (MRD) detection. Our tech stack includes Amazon Web Services (AWS), including Elastic Load Balancing and services within their North Virginia and Stockholm regions. We also utilize DNSSEC for enhanced security and leverage the CrUX dataset for performance monitoring. We foster a collaborative engineering culture focused on delivering innovative solutions. We believe in a data-driven approach and invest heavily in research and development to stay ahead of the curve in genomic diagnostics. SAGA Diagnostics is committed to improving precision cancer medicine. We're a fast-growing company with significant funding, attracting international attention. We prioritize teamwork, innovation, and a positive impact on patient care. We offer remote work opportunities and encourage a diverse and inclusive workplace – where every individual is vital to our success and global reach. With a strong series A funding round secured in 2021, SAGA Diagnostics is rapidly expanding its operations and its impact on cancer diagnostics worldwide. We offer a generous benefits package that includes medical, dental, vision, and paid parental leave, alongside equity participation, reflecting our belief in supporting our employees’ well-being and growth.